Sarah completed her PhD at the MRC Laboratory of Molecular Biology in Cambridge, UK, and was a Beit Memorial Fellow at University College London. She established her research group at the MRC Laboratory of Molecular Biology in 2001, where her main discoveries included the finding that protein assembly pathways are stereotypical and conserved. In 2013, she transitioned to the Wellcome Genome Campus, where she became the first and, to date, the only faculty member appointed across both the EMBL-European Bioinformatics Institute and the Wellcome Sanger Institute. In 2016, she was appointed as the Head of the Cellular Genetics programme at the Wellcome Sanger Institute and co-founded the Human Cell Atlas initiative. From April 2024, she was appointed chair in Stem Cell Medicine at the University of Cambridge, within the Department of Medicine and the Cambridge Stem Cell Institute. Additionally, Sarah dedicates part of her time to GlaxoSmithKline and to EnsoCell Therapeutics, the startup company she co-founded. The Teichmann lab focuses on developing and applying cell atlas technologies to understand human tissue architecture, particularly examining how cellular diversity is generated in the immune system and during development.